Benefits of Partnering with a US-Based CDMO

The mRNA Monthly—August 2024 Newsletter

Rapid Single Epitope mRNA Production This article presents a synthetic DNA template (SDT) process for manufacturing single epitope mRNA, offering a flexible, cost-efficient, and rapid alternative to traditional plasmid DNA templates (PDT). Read the article to explore what can be…

FDA Platform Technology Guidance

Authored by: Christian Cobaugh, Grant Henderson and Khaled Yamout The FDA’s new guidance clarifies eligible Platform Technologies must adhere to the statutory definition and require consistent CMC processes. Applicants can recycle features across products, while those lacking assets can leverage CDMOs like…

Benefits of Partnering with a US-Based CDMO

The mRNA Monthly—July 2024 Newsletter

Phase 2b Autoimmune CAR-T Win Congratulations to Cartesian Therapeutics on their Phase 2b autoimmune CAR-T trial success—shifting the intensity of the cell therapy paradigm! This milestone is a testament to their innovation. It’s exciting to see mRNA as part of…

Benefits of Partnering with a US-Based CDMO

The mRNA Monthly—June 2024 Newsletter

mRNA Capping TechnologiesExplore this study, which compares two important mRNA capping technologies by evaluating the mRNA integrity, percent Cap1 content, dsRNA content, in vivo expression and innate immune activation in mice. Download the Poster 7 Key Benefits of a US-Based…

Benefits of Partnering with a US-Based CDMO

In the fast-paced world of biopharmaceuticals, choosing the right contract development and manufacturing organization (CDMO) is crucial to the success of your drug development program. At Vernal Biosciences, we pride ourselves on being a US-based CDMO that produces all products domestically.   Here…

Benefits of Partnering with a US-Based CDMO

The mRNA Monthly—May 2024 Newsletter

From the FounderWelcome to the NEW monthly mRNA newsletter! In this monthly update, we will share the latest breakthroughs, insights, and innovations in mRNA and mRNA-LNP technology. By reading these updates, you will gain a competitive edge, stay ahead of…

Methods for mRNA poly(A) Sizing

mRNA poly(A) Sizing Methods

Poster Abstract: The mRNA Poly(A) Sizing Methods poster shows the poly (A) tail region of an mRNA functions to stabilize the mRNA and enable translation of the protein. Due to its biological importance of an mRNA’s poly(A) tail, the length…

Doggybone™ DNA for In Vitro Transcription

Poster Abstract: Linear DNA is used as the template to in vitro transcribe (IVT) synthetic mRNA. Common sources for templates are pDNA linearized with a restriction enzyme and PCR amplicons. Enzymatically produced Doggybone™ DNA (dbDNA), is a novel IVT template…

mRNA Capping Technologies

mRNA Capping Technologies

Poster Abstract: Synthetic mRNA is more potent, stable, and immuno-silent when the 5’ end contains a Cap1 structure (N7-methyl guanosine connected to the 5′ nucleotide through a 5′ to 5′ triphosphate linkage; N1 nucleotide methylated at the 2’ position). Cap1…

Poly(A) Tails ​For mRNA Synthesis

Poster Abstract: Poly-adenosine (poly(A)) tails are essential for the translation and stability of mRNA. Most mRNA synthesis processes rely on in vitro transcription(IVT) of mRNA from a linearized plasmid DNA (pDNA) template which includes a region of uninterrupted A-T base…